Zacks Research upgraded shares of Astrazeneca (NYSE:AZN – Free Report) from a strong sell rating to a hold rating in a report published on Tuesday,Zacks reports. A number of other brokerages also recently commented on AZN. Bank of America restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, July 1st. […]

Zacks Research cut shares of Palantir Technologies (NASDAQ:PLTR – Free Report) from a strong-buy rating to a hold rating in a research note released on Tuesday,Zacks reports. PLTR has been the topic of several other reports. BNP Paribas Exane started coverage on shares of Palantir Technologies in a report on Tuesday, June 16th. They set […]

Zacks Research upgraded shares of TG Therapeutics (NASDAQ:TGTX – Free Report) from a strong sell rating to a hold rating in a research report released on Tuesday,Zacks reports. Several other analysts have also recently commented on the company. Jefferies Financial Group reiterated a “buy” rating and issued a $83.00 target price on shares of TG […]

Zacks Research cut shares of CrossAmerica Partners (NYSE:CAPL – Free Report) from a strong-buy rating to a hold rating in a research report report published on Monday,Zacks reports. Separately, Weiss Ratings restated a “hold (c)” rating on shares of CrossAmerica Partners in a research note on Tuesday, September 8th. Two research analysts have rated the […]

Quince Therapeutics (NASDAQ:QNCX – Get Free Report) was upgraded by stock analysts at Zacks Research to a “hold” rating in a note issued to investors on Thursday, Zacks reports. QNCX has been the topic of a number of other research reports. Lifesci Capital upgraded shares of Quince Therapeutics to a “strong-buy” rating in a report […]